If so, it really is congruous to predict a NPS agonist- or antagonist-based therapy would inevitably fail in homozygous companies of the Phe on the Cys197Pthis individual polymorphic site
If so, it really is congruous to predict a NPS agonist- or antagonist-based therapy would inevitably fail in homozygous companies of the Phe on the Cys197Pthis...